Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
University of Georgia, Athens, GA, USA.
Mark H
MH
Ebell
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004763:Glucagon-Like Peptides / Q000008:administration & dosage*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D016896:Treatment Outcome; D000099194:Semaglutide
D004763:Glucagon-Like Peptides; D007004:Hypoglycemic Agents; D000099194:Semaglutide